Skip to main content
Top
Published in: Inflammation 4/2014

01-08-2014

Bufalin, a Bioactive Component of the Chinese Medicine Chansu, Inhibits Inflammation and Invasion of Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes

Authors: Xiaofeng Rong, Weidong Ni, Yongguang Liu, Jun Wen, Chunyan Qian, Linke Sun, Jiajia Wang

Published in: Inflammation | Issue 4/2014

Login to get access

Abstract

Rheumatoid arthritis fibroblast-like synoviocytes (RAFLSs) contribute to the destruction of cartilage and bone by production of metalloproteinases (MMPs) into the synovial fluid and by direct invasion into extracellular matrix (ECM). Bufalin, a major component of Venenum Bufonis, can attenuate the invasion of various cancer cells. Here, we investigated the effects of bufalin on tumor necrosis factor-alpha (TNF-α)-induced invasion of RAFLSs. Western blot analysis and electrophoretic mobility shift assay were conducted to analyze the nuclear translocation of p65/nuclear factor-kappa B (NF-κB) and NF-κB DNA-binding activity. Semiquantitative reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay were performed to assess the expression of cytokines. Our results revealed that TNF-α significantly increased p65 translocation into nucleus (P < 0.01) and enhanced NF-κB DNA-binding activity, which were dose-dependently inhibited by bufalin. Furthermore, bufalin attenuated the TNF-α-induced interleukin-1beta (IL-1β), IL-6, and IL-8 production in RAFLSs in a concentration-dependent manner. Interestingly, TNF-α-induced invasion of RAFLSs was dampened by the pretreatment of bufalin. Additionally, bufalin decreased the mRNA abundance and secretion of MMP-9 in TNF-α-treated RAFLSs. Our results reveal that bufalin can inhibit TNF-α-induced NF-κB activation, cytokine production, invasion, and MMP-9 expression in RAFLSs, indicating a therapeutic potential of bufalin on RA.
Literature
1.
go back to reference Huber, L.C., O. Distler, I. Tarner, R.E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45: 669–675.PubMedCrossRef Huber, L.C., O. Distler, I. Tarner, R.E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45: 669–675.PubMedCrossRef
2.
go back to reference Lafyatis, R., N.L. Thompson, E.F. Remmers, K.C. Flanders, N.S. Roche, S.J. Kim, J.P. Case, M.B. Sporn, A.B. Roberts, and R.L. Wilder. 1989. Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. Journal of Immunology 143: 1142–1148. Lafyatis, R., N.L. Thompson, E.F. Remmers, K.C. Flanders, N.S. Roche, S.J. Kim, J.P. Case, M.B. Sporn, A.B. Roberts, and R.L. Wilder. 1989. Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. Journal of Immunology 143: 1142–1148.
3.
go back to reference Chu, C.Q., M. Field, M. Feldmann, and R.N. Maini. 1991. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis and Rheumatism 34: 1125–1132.PubMedCrossRef Chu, C.Q., M. Field, M. Feldmann, and R.N. Maini. 1991. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis and Rheumatism 34: 1125–1132.PubMedCrossRef
4.
go back to reference Chu, C.Q., M. Field, S. Allard, E. Abney, M. Feldmann, and R.N. Maini. 1992. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. British Journal of Rheumatology 31: 653–661.PubMedCrossRef Chu, C.Q., M. Field, S. Allard, E. Abney, M. Feldmann, and R.N. Maini. 1992. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. British Journal of Rheumatology 31: 653–661.PubMedCrossRef
5.
go back to reference Feldmann, M. 2001. Pathogenesis of arthritis: recent research progression. Nature Immunology 2: 771–773.PubMedCrossRef Feldmann, M. 2001. Pathogenesis of arthritis: recent research progression. Nature Immunology 2: 771–773.PubMedCrossRef
6.
go back to reference Han, Z.N., D.L. Boyle, A.M. Manning, and G.S. Firestein. 1998. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197–208.PubMedCrossRef Han, Z.N., D.L. Boyle, A.M. Manning, and G.S. Firestein. 1998. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197–208.PubMedCrossRef
7.
go back to reference Handel, M.L., L.B. McMorrow, and E.M. Gravallese. 1995. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis and Rheumatism 38: 1762–1770.PubMedCrossRef Handel, M.L., L.B. McMorrow, and E.M. Gravallese. 1995. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis and Rheumatism 38: 1762–1770.PubMedCrossRef
8.
go back to reference Granet, C., W. Maslinski, and P. Miossec. 2004. Increased AP-1 and NF-κB activation and recruitment with the combination of the proinflammatory cytokines IL-1, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Research and Therapy 6: R190–R198.PubMedCentralPubMedCrossRef Granet, C., W. Maslinski, and P. Miossec. 2004. Increased AP-1 and NF-κB activation and recruitment with the combination of the proinflammatory cytokines IL-1, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Research and Therapy 6: R190–R198.PubMedCentralPubMedCrossRef
9.
go back to reference Miyazawa, K., A. Mori, K. Yamamoto, and H. Okudaira. 1998. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-κB and CBF1. American Journal of Pathology 152: 793–803.PubMedCentralPubMed Miyazawa, K., A. Mori, K. Yamamoto, and H. Okudaira. 1998. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-κB and CBF1. American Journal of Pathology 152: 793–803.PubMedCentralPubMed
10.
go back to reference Seetharaman, R., A.L. Mora, G. Nabozny, M. Boothby, and J. Chen. 1999. Essential role of T cell NF-kappaB activation in collagen-induced arthritis. Journal of Immunology 163: 1577–1583. Seetharaman, R., A.L. Mora, G. Nabozny, M. Boothby, and J. Chen. 1999. Essential role of T cell NF-kappaB activation in collagen-induced arthritis. Journal of Immunology 163: 1577–1583.
11.
go back to reference Miagkov, A.V., D.V. Kovalenko, C.E. Brown, J.R. Didsbury, J.P. Cogswell, S.A. Stimpson, A.S. Baldwin, and S.S. Makarov. 1998. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proceedings of the National Academy of Sciences of the United States of America 95: 13859–13864.PubMedCentralPubMedCrossRef Miagkov, A.V., D.V. Kovalenko, C.E. Brown, J.R. Didsbury, J.P. Cogswell, S.A. Stimpson, A.S. Baldwin, and S.S. Makarov. 1998. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proceedings of the National Academy of Sciences of the United States of America 95: 13859–13864.PubMedCentralPubMedCrossRef
12.
go back to reference Tak, P.P., D.M. Gerlag, K.R. Aupperle, D.A. van de Geest, M. Overbeek, B.L. Bennett, D.L. Boyle, A.M. Manning, and G.S. Firestein. 2001. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis and Rheumatism 44: 1897–1907.PubMedCrossRef Tak, P.P., D.M. Gerlag, K.R. Aupperle, D.A. van de Geest, M. Overbeek, B.L. Bennett, D.L. Boyle, A.M. Manning, and G.S. Firestein. 2001. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis and Rheumatism 44: 1897–1907.PubMedCrossRef
13.
go back to reference Hammaker, D., S. Sweeney, and G.S. Firestein. 2003. Signal transduction networks in rheumatoid arthritis. Annals of the Rheumatic Diseases 62: 1186–1189.CrossRef Hammaker, D., S. Sweeney, and G.S. Firestein. 2003. Signal transduction networks in rheumatoid arthritis. Annals of the Rheumatic Diseases 62: 1186–1189.CrossRef
14.
go back to reference Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunology Reviews 233: 233–255.CrossRef Bartok, B., and G.S. Firestein. 2010. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunology Reviews 233: 233–255.CrossRef
15.
go back to reference Karouzakis, E., R.E. Gay, S. Gay, and M. Neidhart. 2009. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nature Reviews. Rheumatology 5: 266–272.PubMedCrossRef Karouzakis, E., R.E. Gay, S. Gay, and M. Neidhart. 2009. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nature Reviews. Rheumatology 5: 266–272.PubMedCrossRef
16.
go back to reference Smolen, J.S., D. Aletaha, M. Koeller, M.H. Weisman, and P. Emery. 2007. New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861–1874.PubMedCrossRef Smolen, J.S., D. Aletaha, M. Koeller, M.H. Weisman, and P. Emery. 2007. New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861–1874.PubMedCrossRef
17.
go back to reference Smolen, J.S., and G. Steiner. 2003. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery 2: 473–488.PubMedCrossRef Smolen, J.S., and G. Steiner. 2003. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery 2: 473–488.PubMedCrossRef
18.
go back to reference Yin, P., Y. Wang, Y. Qiu, L. Hou, X. Liu, J. Qin, Y. Duan, P. Liu, M. Qiu, and Q. Li. 2012. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. International Journal of Nanomedicine 7: 3961–3969.PubMedCentralPubMed Yin, P., Y. Wang, Y. Qiu, L. Hou, X. Liu, J. Qin, Y. Duan, P. Liu, M. Qiu, and Q. Li. 2012. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. International Journal of Nanomedicine 7: 3961–3969.PubMedCentralPubMed
19.
go back to reference Hong, S.H., G.Y. Kim, Y.C. Chang, S.K. Moon, W.J. Kim, and Y.H. Choi. 2013. Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions. International Journal of Oncology 42: 277–286.PubMed Hong, S.H., G.Y. Kim, Y.C. Chang, S.K. Moon, W.J. Kim, and Y.H. Choi. 2013. Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions. International Journal of Oncology 42: 277–286.PubMed
20.
go back to reference Chueh, F.S., Y.Y. Chen, A.C. Huang, H.C. Ho, C.L. Liao, J.S. Yang, C.L. Kuo, and J.G. Chung. 2014. Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. Environmental Toxicology 29: 21–29.PubMedCrossRef Chueh, F.S., Y.Y. Chen, A.C. Huang, H.C. Ho, C.L. Liao, J.S. Yang, C.L. Kuo, and J.G. Chung. 2014. Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. Environmental Toxicology 29: 21–29.PubMedCrossRef
21.
go back to reference Chen, Y.Y., H.F. Lu, S.C. Hsu, C.L. Kuo, S.J. Chang, J.J. Lin, P.P. Wu, J.Y. Liu, C.H. Lee, J.G. Chung, and J.B. Chang. 2013. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways. Environmental Toxicology. doi:10.1002/tox.21896. Chen, Y.Y., H.F. Lu, S.C. Hsu, C.L. Kuo, S.J. Chang, J.J. Lin, P.P. Wu, J.Y. Liu, C.H. Lee, J.G. Chung, and J.B. Chang. 2013. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase-2/-9-signaling pathways. Environmental Toxicology. doi:10.​1002/​tox.​21896.
22.
go back to reference Qiu, D.Z., Z.J. Zhang, W.Z. Wu, and Y.K. Yang. 2013. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC Complementary and Alternative Medicine 13: 185.PubMedCentralPubMedCrossRef Qiu, D.Z., Z.J. Zhang, W.Z. Wu, and Y.K. Yang. 2013. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC Complementary and Alternative Medicine 13: 185.PubMedCentralPubMedCrossRef
23.
go back to reference Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.PubMedCrossRef Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 31: 315–324.PubMedCrossRef
24.
go back to reference Li, G., D. Liu, Y. Zhang, Y. Qian, H. Zhang, S. Guo, M. Sunagawa, T. Hisamitsu, and Y. Liu. 2013. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-κB-mediated matrix metalloproteinase-9 expression. PLoS One 8: e68905.PubMedCentralPubMedCrossRef Li, G., D. Liu, Y. Zhang, Y. Qian, H. Zhang, S. Guo, M. Sunagawa, T. Hisamitsu, and Y. Liu. 2013. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-κB-mediated matrix metalloproteinase-9 expression. PLoS One 8: e68905.PubMedCentralPubMedCrossRef
25.
26.
go back to reference Makarov, S.S. 2001. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Research 3: 200–206.PubMedCentralPubMedCrossRef Makarov, S.S. 2001. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Research 3: 200–206.PubMedCentralPubMedCrossRef
27.
go back to reference Chen, D.P., C.K. Wong, P.C. Leung, K.P. Fung, C.B. Lau, C.P. Lau, E.K. Li, L.S. Tam, and C.W. Lam. 2011. Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of Ethnopharmacology 137: 457–468.PubMedCrossRef Chen, D.P., C.K. Wong, P.C. Leung, K.P. Fung, C.B. Lau, C.P. Lau, E.K. Li, L.S. Tam, and C.W. Lam. 2011. Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. Journal of Ethnopharmacology 137: 457–468.PubMedCrossRef
28.
go back to reference Chen, A., J. Yu, L. Zhang, Y. Sun, Y. Zhang, H. Guo, Y. Zhou, K. Mitchelson, and J. Cheng. 2009. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 cells. Biotechnology Letters 31: 487–494.PubMedCrossRef Chen, A., J. Yu, L. Zhang, Y. Sun, Y. Zhang, H. Guo, Y. Zhou, K. Mitchelson, and J. Cheng. 2009. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 cells. Biotechnology Letters 31: 487–494.PubMedCrossRef
29.
go back to reference Xu, H., Y. He, X. Yang, L. Liang, Z. Zhan, Y. Ye, X. Yang, F. Lian, and L. Sun. 2007. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 46: 920–926.CrossRef Xu, H., Y. He, X. Yang, L. Liang, Z. Zhan, Y. Ye, X. Yang, F. Lian, and L. Sun. 2007. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 46: 920–926.CrossRef
30.
go back to reference Tolboom, T.C., E. Pieterman, W.H. van der Laan, R.E. Toes, A.L. Huidekoper, R.G. Nelissen, F.C. Breedveld, and T.W. Huizinga. 2002. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Annals of the Rheumatic Diseases 61: 975–980.PubMedCentralPubMedCrossRef Tolboom, T.C., E. Pieterman, W.H. van der Laan, R.E. Toes, A.L. Huidekoper, R.G. Nelissen, F.C. Breedveld, and T.W. Huizinga. 2002. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Annals of the Rheumatic Diseases 61: 975–980.PubMedCentralPubMedCrossRef
31.
go back to reference Fragoulis, A., J. Laufs, S. Müller, U. Soppa, S. Siegl, L.K. Reiss, M. Tohidnezhad, C. Rosen, K. Tenbrock, D. Varoga, S. Lippross, T. Pufe, and C.J. Wruck. 2012. Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes. Arthritis Research and Therapy 14: R220.PubMedCentralPubMedCrossRef Fragoulis, A., J. Laufs, S. Müller, U. Soppa, S. Siegl, L.K. Reiss, M. Tohidnezhad, C. Rosen, K. Tenbrock, D. Varoga, S. Lippross, T. Pufe, and C.J. Wruck. 2012. Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes. Arthritis Research and Therapy 14: R220.PubMedCentralPubMedCrossRef
Metadata
Title
Bufalin, a Bioactive Component of the Chinese Medicine Chansu, Inhibits Inflammation and Invasion of Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Authors
Xiaofeng Rong
Weidong Ni
Yongguang Liu
Jun Wen
Chunyan Qian
Linke Sun
Jiajia Wang
Publication date
01-08-2014
Publisher
Springer US
Published in
Inflammation / Issue 4/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9828-y

Other articles of this Issue 4/2014

Inflammation 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.